Four new us patents granted to Acrux for transdermal drug delivery

Main Category: Medical Devices / Diagnostics
Article Date: 27 Sep 2005 - 0:00 PDT

email to a friend   printer friendly   opinions  

Acrux Limited, the Australian pharmaceutical company that specialises in products delivering therapeutic drugs through the skin, today announced that it has been granted four more US patents relating to its transdermal drug delivery technology.

The four US patents provide additional protection for systemic delivery of drugs in specific therapeutic areas, namely analgesics (US patent number 6,916,486), hormones (6,923,983), anti-Parkinson's agents (6,929,801) and anti-emetics (6,916,487). These are "continuation in part" patents, related to Acrux's US patent number 6,818,226.

The new patents, which expire in February 2017, further extend the proprietary nature of Acrux's transdermal drug delivery technology for a number of products in the current pipeline. They provide protection for transdermal drug delivery systems, in the specific therapy areas, that consist of an effective amount of physiologically active agent (e.g. a therapeutic drug), a dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen, and a volatile liquid. Acrux now has six patents granted in the USA.

Acrux CEO and Managing Director, Dr Igor Gonda said: "These new US patents provide additional protection for our products in our core areas of interest. Our patenting activity is at the heart of our business strategy to develop and commercialise patient-preferred patent-protected healthcare products for valuable global markets."

Igor Gonda
61-383-790-100
Research Australia
http://www.researchaustralia.com.au

• Additional
• References
• Citations